Sangamo Therapeuticsincis A Biotechnology Company Based In Brisbanecaliforniafocused On Genomic Medicinefounded In 1995 And Rebranded In 2017Sangamo Specializes In Developing Cell And Gene Therapies For Severe Genetic And Neurological Disordersthe Company Utilizes Proprietary Zinc Finger Proteinzfptechnology For Precise Gene Regulation And Genome Editing Sangamo S Therapeutic Pipeline Targets Conditions Such As Hemophiliahuntingtonae S Diseasefabry Diseaseand Alzheimerae Sthe Company Employs Zinc Finger Nucleases For Genome Editing And Has Established Partnershipsincluding A Collaboration With Genentech For Neurology Focused Drug Developmentwith A Commitment To Addressing Unmet Medical Needssangamo Aims To Translate Genomic Science Into Effective Therapies For Patients Facing Limited Treatment Options
